Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) and Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, profitability, risk and earnings.
Valuation and Earnings
This table compares Aclaris Therapeutics and Amneal Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aclaris Therapeutics | $7.83 million | 89.18 | -$64.92 million | ($0.56) | -8.93 |
| Amneal Pharmaceuticals | $3.02 billion | 1.82 | $72.06 million | $0.38 | 45.34 |
Analyst Ratings
This is a summary of recent ratings and target prices for Aclaris Therapeutics and Amneal Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aclaris Therapeutics | 1 | 0 | 4 | 3 | 3.13 |
| Amneal Pharmaceuticals | 0 | 2 | 5 | 0 | 2.71 |
Aclaris Therapeutics presently has a consensus target price of $11.50, suggesting a potential upside of 130.00%. Amneal Pharmaceuticals has a consensus target price of $15.80, suggesting a potential downside of 8.30%. Given Aclaris Therapeutics’ stronger consensus rating and higher possible upside, research analysts clearly believe Aclaris Therapeutics is more favorable than Amneal Pharmaceuticals.
Insider and Institutional Ownership
98.3% of Aclaris Therapeutics shares are held by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 4.8% of Aclaris Therapeutics shares are held by company insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Risk and Volatility
Aclaris Therapeutics has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500. Comparatively, Amneal Pharmaceuticals has a beta of 1.3, meaning that its stock price is 30% more volatile than the S&P 500.
Profitability
This table compares Aclaris Therapeutics and Amneal Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aclaris Therapeutics | -832.58% | -55.89% | -38.49% |
| Amneal Pharmaceuticals | 4.01% | -313.96% | 7.49% |
Summary
Amneal Pharmaceuticals beats Aclaris Therapeutics on 9 of the 15 factors compared between the two stocks.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
About Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
